Gene therapy of epidermolysis bullosa

Bibliography

• UITTO J, PULKKINEN L: Molecular genetics of heritable blistering disorders. Arch. Dermatol. (2001) 137:1458–1461.
   PubMed Web of Science ®Google Scholar
• DUNNWALD M, TOMANEK-CHALKLEY A, ALEXANDRUNAS D, FISHBAUGH J, BICKENBACH JR: Isolating a pure population of epidermal stem cells for use in tissue engineering. Exp. Dermatol. (2001) 10:45–54.
   PubMed Web of Science ®Google Scholar
• LI A, POULIOT N, REDVERS R, KAUR P: Extensive tissue-regenerative capacity of neonatal human keratinocyte stem cells and their progeny. Clin. Invest. (2004) 113:390–400.
   Google Scholar
• MORRIS RJ, LIU Y, MARLES L et al.: Capturing and profiling adult hair follicle stem cells. Nat. Biotechnol. (2004) 22:411–417.
   PubMed Web of Science ®Google Scholar
• TUMBAR T, GUASCH G, GRECO V et al.: Defining the epithelial stem cell niche in skin. Science (2004) 303:359–363.
   PubMed Web of Science ®Google Scholar
• KOLODKA TM, GARLICK JA, TAICHMAN LB: Evidence for KC stem cells in vitro: long term engraftment and persistence of transgene expression from retrovirus-transduced keratinocytes. Proc. Nati Acad. Sci. USA (1998) 95:4356–4361.
   PubMed Web of Science ®Google Scholar
• VANDENDRIESSCHE T, COLLEN D,CHUAH MK: Gene therapy for the hemophilias. Thromb. Haemost. (2003) 1:1550–1558.
   Web of Science ®Google Scholar
• LOWENSTEIN PR: Virology and immunology of gene therapy, or virology and immunology of high MOI infection with defective viruses. Gene The]: (2003) 10:933–998.
   PubMed Web of Science ®Google Scholar
• VOGEL J: The virtue of tolerance. Invest.Dermatol. (2003) 120:610–615.
   PubMed Web of Science ®Google Scholar
• IRVINE AD, MCLEAN WH: Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br.j Dermatol. (1999) 140:815–828.
   PubMed Web of Science ®Google Scholar
• MAGIN TM, KAISER HW, LEITGEB S et al.: Supplementation of a mutant keratin by stable expression of desmin in cultured human EBS KCs. I Cell Sci. (2000) 113:4231–4239.
   PubMed Web of Science ®Google Scholar
• KIRFEL J, PETERS B, GRUND C, REIFENBERG K, MAGIN TM: Ectopic expression of desmin in the epidermis of transgenic mice permits development of a normal epidermis. Differentiation (2002) 70:56–68.
   PubMed Web of Science ®Google Scholar
• JENSEN TG, SORENSEN CB, JENSEN UB, BOLUND L: Epidermolysis bullosa simplex keratinocytes with extended lifespan established by ectopic expression of telomerase. Exp. Dermatol. (2003) 12:71–77.
   PubMed Web of Science ®Google Scholar
• CAO T, LONGLEY MA, WANG XJ, ROOP DR: An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy.' Cell. Biol. (2001) 152:651–656.
   PubMed Web of Science ®Google Scholar
• •A first dynamic mouse model of EB.
   Google Scholar
• POHLA-GUBO G, LAZAROVA Z, GIUDICE GJ et al.: Diminished expression of the extracellular domain of bullous pemphigoid antigen 2 (BPAG2) in the epidermal basement membrane of patients with generalized atrophic benign epidermolysis bullosa. Exp. Dermatol. (1995) 4:199–206.
   PubMedGoogle Scholar
• MCGRATH JA, GATALICA B, CHRISTIANO AM et al.: Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL I7A1), in generalized atrophic benign epidermolysis bullosa. Nat. Genet. (1995) 11:83–86.
   PubMed Web of Science ®Google Scholar
• CHRISTIANO AM, PULKKINEN L, EADY RA, UITTO J: Compound heterozygosity for nonsense and missense mutations in the LAMB3gene in nonlethal junctional epidermolysis bullosa. Invest. Dermatol. (1996) 106:775–777.
   PubMed Web of Science ®Google Scholar
• SEITZ CS, GIUDICE GJ, BALDING SD, MARINKOVICH MP, KHAVARI PA: BP180 gene delivery in junctional epidermolysis bullosa. Gene Thec (1999) 6:42–47.
   PubMed Web of Science ®Google Scholar
• DELLAMBRA E, VAILLY J, PELLEGRINI G et al.: Corrective
   Google Scholar
• •• transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa. Hum. Gene Ther. (1998) 9:1359–1370.
   PubMed Web of Science ®Google Scholar
• ••The first successful attempt to amend thephenotype of EB in a mouse-human xenotransplantation system.
   Google Scholar
• VAILLY J, GAGNOUX-PALACIOS L, DELL'AMBRA E et al.: Corrective gene transfer of KCs from patients with junctional epidermolysis bullosa restores assembly of hemidesmosomes in reconstructed epithelia. Gene Ther. (1998) 5:1322–1332.
   Google Scholar
• ROBBINS PB, LIN Q, GOODNOUGH JB, TIAN H, CHEN X, KHAVARI PA: In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc. Nati Acad. Sri. USA (2001) 98:5193–5198.
   PubMed Web of Science ®Google Scholar
• ROBBINS PB, SHEU SM, GOODNOUGH JB, KHAVARI PA: Impact of laminin 5 beta3 gene versus protein replacement on gene expression patterns in junctional epidermolysis bullosa. Hum. Gene The]: (2001) 12:1443–1448.
   Google Scholar
• •Molecular characterisation of the phenotypic correction suggesting that gene therapy is better than protein therapy.
   Google Scholar
• ORTIZ-URDA S, THYAGARAJAN B, KEENE DR, LIN Q, CALOS MP, KHAVARI PA: PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum. Gene Ther. (2003) 14:923–928.
   PubMed Web of Science ®Google Scholar
• ORTIZ-URDA S, LIN Q, YANT SR, KEENE D, KAY MA, KHAVARI PA: Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene The]: (2003) 10:1099–1104.
   PubMed Web of Science ®Google Scholar
• DELLAMBRA E, PRISLEI S, SALVATI ALet al.: Gene correction of integrin beta4-dependent pyloric atresia-junctional epidermolysis bullosa keratinocytes establishes a role for beta4 tyrosines 1422 and 1440 in hemidesmosome assembly. J. Biol. Chem. (2001) 276:41336–41342.
   Google Scholar
• SATE, LEUNG KH, BRUCKNER-TUDERMAN L, CHEAH KS: Tissue-specific expression and long-term deposition of human collagen VII in the skin of transgenic mice: implications for gene therapy. Gene Ther. (2000) 7:1631–1639.
   PubMed Web of Science ®Google Scholar
• MECKLENBECK S, COMPTON SH, MEJIA JE et al.: A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line. Hum. Gene Ther. (2002) 13:1655–1662.
   PubMed Web of Science ®Google Scholar
• CHEN M, KASAHARA N, KEENE DR et al.: Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat. Genet. (2002) 32:670–675.
   PubMed Web of Science ®Google Scholar
• •A first DEB phenotype using full-length type VII collagen in a lentiviral vector.
   Google Scholar
• ORTIZ-URDA S, THYAGARAJAN B, KEENE DR et al.: Stable nonviral genetic correction of inherited human skin disease. Nat. Med. (2002) 8:1166–1170.
   PubMed Web of Science ®Google Scholar
• •Using PhiC31 integrase, the full-length type VII collagen eDNA was shown to repair regenerated human skin tissue from a RDEB patient.
   Google Scholar
• ORTIZ-URDA S, LIN Q, GREEN CL, KEENE DR, MARINKOVICH MP, KHAVARI PA: Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. I Clin. Invest. (2003) 111:251–255.
   PubMed Web of Science ®Google Scholar
• WOODLEY DT, KRUEGER GG, JORGENSEN CM et al.: Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J. Invest. Dermatol. (2003) 121:1021–1028.
   PubMed Web of Science ®Google Scholar
• BALDESCHI C, GACHE Y, RATTENHOLL A et al.: Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum. Mol. Genet. (2003) 12:1897–1905.
   PubMed Web of Science ®Google Scholar
• PETERS B, KIRFEL J, BUESSOW H, VIDAL M, MAGIN TM: Complete cytolysis and neonatal lethality in keratin 5 knockout mice reveal its fundamental role in skin integrity and in epidermolysis bullosa simplex. Mol. Biol. Cell (2001) 12:1775–1786.
   PubMed Web of Science ®Google Scholar
• LLOYD C, YU QC, CHENG J et al.: Thebasal keratin network of stratified squamous epithelia: defining K15 function in the absence of K14./ Cell. Biol. (1995) 129:1329–1344.
   Google Scholar
• RYAN M, LEE K, MIYASHITA Y, CARTER WG: Targeted disruption of the LAMA3 gene in mice reveals abnormalities in survival and late stage differentiation of epithelial cells. Cell. Biol. (1999) 145:1309–1323.
   PubMed Web of Science ®Google Scholar
• MENG X, KLEMENT JF, LEPERI DA et al.: Targeted inactivation of murine gamma2-chain gene recapitulates human junctional epidermolysis bullosa. Invest. Dermatol. (2003) 121:720–731.
   PubMed Web of Science ®Google Scholar
• GEORGE-LABOUESSE E, MESSADEQ N, YEHIA G, CADALBERT L, DIERICH A, LE MEUR M: Absence of integrin alpha 6 leads to epidermolysis bullosa and neonatal death in mice. Nat. Genet. (1996) 13:370–373.
   PubMed Web of Science ®Google Scholar
• VAN DER NEUT R, KRIMPENFORT P, CALAFAT J, NIESSEN CM, SONNENBERG A: Epithelial detachment due to absence of hemidesmosomes in integrin beta4 null mice. Nat. Genet. (1996) 13:366–369.
   PubMed Web of Science ®Google Scholar
• HEINONEN S, MANNIKO M, KLEMENT JF, WHITAKER-MENEZES D, MURPHY GE UITTO J: Targeted inactivation of the type VII collagen gene (COL7A1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. I Cell. Sri. (1999) 112:3641–3648.
   PubMed Web of Science ®Google Scholar
• SPIRITO F, CHARLESWORTH A, LINDER K, ORTONNE JP, BAIRD J, MENEGUZZI G: Animal models for skin blistering conditions: absence of laminin 5 causes hereditary junctional mechanobullous disease in the Belgian horse. J. Invest. Dermatol. (2002) 119:684–691.
   PubMed Web of Science ®Google Scholar
• PALAZZI X, MARCHAL T, CHABANNE L, SPADAFORA A, MAGNOL JP, MENEGUZZI G: Inherited dystrophic epidermolysis bullosa in inbred dogs: a spontaneous animal model for somatic gene therapy. J. Invest. Dermatol. (2000) 115:135–137.
   PubMed Web of Science ®Google Scholar
• JONKMAN ME SCHEFFER H, STULP R et al.: Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell (1997) 88:543–551.
   PubMed Web of Science ®Google Scholar
• ••An experiment of nature shows that cDNAgene therapy is a feasible approach.
   Google Scholar
• DARLING TN, YEE C, BAUER JW, HINTNER H, YANCEY KB: Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation. J. Clin. Invest (1999) 103:1371–1377.
   PubMed Web of Science ®Google Scholar
• SMITH FJ, MORLEY SM, MCLEAN WH: Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex. Invest. Dermatol. (2004) 122:73–77.
   PubMed Web of Science ®Google Scholar
• LACERRA G, SIERAKOWSKA H, CARESTIA C et al.: Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA (2000) 97:9591–9596.
   PubMed Web of Science ®Google Scholar
• RUZZI L, PAS H, POSTERARO P et al:A homozygous nonsense mutation in type XVII collagen gene (COL 17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. Invest. Dermatol (2001) 116:182–187.
   PubMed Web of Science ®Google Scholar
• MCGRATH JA, ASHTON GH, MELLERIO JE et al.: Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations. J. Invest. Dermatol (1999) 113:314–321.
   PubMed Web of Science ®Google Scholar
• HOFMANN Y, LORSON CL, STAMM S, ANDROPHY EJ, WIRTH B: Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc. Nati Acad. Sci. USA (2000) 97:9618–9623.
   PubMed Web of Science ®Google Scholar
• LAN N, HOWREY RP, LEE SW, SMITH CA, SULLENGER BA: Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science (1998) 280:1593–1596.
   PubMed Web of Science ®Google Scholar
• ••Targeted trans-splicing used to repairgenetic diseases.
   Google Scholar
• PUTTARAJU M, JAMISON SF, MANSFIELD SG, GARCIA-BLANCO MA, MITCHELL LG: Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat. Biotechnol (1999) 17:246–252.
   PubMed Web of Science ®Google Scholar
• LIU X, JIANG Q, MANSFIELD SG et al.:Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat. Biotechnol (2002) 20:47–52.
   PubMed Web of Science ®Google Scholar
• CHAO H, MANSFIELD SG, BARTEL RC et al: Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat. Med. (2003) 9:1015–1019.
   PubMed Web of Science ®Google Scholar
• DALLINGER G, PUTTARAJU M, MITCHELL LG et al.: Development of spliceosome-mediated RNA trans-splicing (SMaRT trade mark) for the correction of inherited skin diseases. Exp. Dermatol (2003) 12:37–46.
   PubMed Web of Science ®Google Scholar
• SINGH A, URSIC D, DAVIES J: Phenotypic suppression and misreading Saccharomyces cerevisiae. Nature (1979) 277:146–148.
   PubMed Web of Science ®Google Scholar
• BARTON-DAVIS ER, CORDIER L, SHOTURMA DI, LELAND SE, SWEENEY HL: Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest (1999) 104:375–381.
   PubMed Web of Science ®Google Scholar
• •The application of a long known antibiotic for gene therapy.
   Google Scholar
• WAGNER KR, HAMED S, HADLEY DW et al.: Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol (2001) 49:706–711.
   PubMed Web of Science ®Google Scholar
• POLITANO L, NIGRO G, NIGRO V et al.: Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. (2003) 22:15–21.
   PubMedGoogle Scholar
• HOWARD MT, SHIRTS BH, PETROS LM, FLANIGAN KM, GESTELAND RF, ATKINS JF: Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol (2000) 48:164–169.
   PubMed Web of Science ®Google Scholar
• WILSCHANSKI M, YAHAV Y, YAACOV Y et al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl. I Med. (2003) 349:1433–1441.
   PubMed Web of Science ®Google Scholar
• •In certain instances, gentarnicin also works in the human system.
   Google Scholar
• ARAKAWA M, SHIOZUKA M, NAKAYAMA Y et al.: Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. I Biochem. (Tokyo) (2003) 134:751–758.
   PubMed Web of Science ®Google Scholar
• BODEMER C, TCHEN SI, GHOMRASSENI S et al: Skin expression of metalloproteinases and tissue inhibitor of metalloproteinases in sibling patients with recessive dystrophic epidermolysis and intrafamilial phenotypic variation. J. Invest. Dermatol (2003) 121:273–279.
   PubMed Web of Science ®Google Scholar
• HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: LM02-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302:415–419.
   PubMed Web of Science ®Google Scholar
• ••The insertion into a tumour-suppressorgene described here led to a transient halt of retroviral-based gene therapy trials.
   Google Scholar
• CAVAZZANA-CALVO M, TRASHER A, MAVILIO F: The future of gene therapy. Nature (2004) 427:779–781.
   PubMed Web of Science ®Google Scholar
• MCLEAN I, TERRON A: Ribozyme gene therapy strategies for keratin disorders. J. Invest. Dermatol (2002) 119:268.
   Web of Science ®Google Scholar